Molecular Vision: Wei, Mol Vis 2011; 17:1449-1456. Table 2

Table 2. Phenotype characteristic of mutation carriers in PN pedigree.

			BCVA		IOP max before Treatment (mmHg)		C/D		Visual Field Loss			Postoperative IOP max (mmHg)
Subject number)	Age at diagnosis/Age (years)	Gender	OD	OS	OD	OS	OD	OS	OD	OS	Treatment	OD	OS
III1	28/68	F	HM	0.15	40	38	1.0	1.0	N/A	Yes	Trab OU	10	11
IV1	20/46	M	0.5	0.4	35	37	1.0	1.0	Yes	Yes	Trab OU	9	12
IV3	26/43	F	0.8	0.8	32	35	0.5	0.7	Yes	Yes	Trab OU	13	12
IV8	18/36	M	0.9	0.8	36	35	0.9	0.8	Yes	Yes	Trab OU	8	9
V2	15/20	F	0.8	0.8	36	33	0.7	0.6	Yes	Yes	Trab OU	9	10
V4	12/16	F	1.0	0.8	35	33	0.6	0.5	Yes	Yes	Trab OU	13	11
V5	10/14	M	1.2	1.5	31	32	0.6	0.6	Yes	No	Trab OU	14	12
V6	9/13	M	1.5	1.5	30	29	0.4	0.5	No	No	Med OU

The Pro370Leu mutation was present in all eight subjects in the table. Seven patients in the table had undergone trabeculectomy surgery to both eyes. Abbreviations in the table are: JOAG; juvenile open-angle glaucoma, BCVA; best-correct visual activity, RE; right eye, LE; left eye, IOP; intraocular pressure, C/D; cup disk ratio, V; vertical, H; horizontal, VF; visual field, F; female, M; male,OU; both eyes, N; normal, IZD; indicated inferior zone defect, NLP; no light perception, LP; light perception, and HM; hand movement, PC; poor cooperation, N/A; unavailable.